Ricevi le ultime notizie sulle azioni Cytokinetics con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di CYTK

Ultime notizie per

CYTOKINETICS INC

Cytokinetics

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Cytokinetics, Incorporated - Common Stock

Cytokinetics Inc

News

Legal

Press Releases

DEADLINE ALERT for LNTH, VFC, FLR, CYTK: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

Cytokinetics, Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CYTK

CYTK Investors Have Opportunity to Join Cytokinetics, Incorporated Fraud Investigation with the Schall Law Firm

Bragar Eagel & Squire, P.C. Reminds Investors of VFC, Cytokinetics, Quanex, and RCI that Class Action Lawsuits Have Been Filed and Encourages Investors to Contact the Firm

CYTOKINETICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cytokinetics, Incorporated - CYTK

Class Action Filed Against Cytokinetics, Incorporated (CYTK) - November 17, 2025 Deadline to Join - Contact Levi & Korsinsky

Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Levi & Korsinsky Reminds Cytokinetics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 17, 2025 – CYTK

NATIONALLY RANKED ROSEN LAW FIRM Encourages Cytokinetics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CYTK

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics

CYTK

LNTH

RICK

Abivax

Alkermes

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharma

BridgeBio Pharma

BioMarin Pharmaceutical Inc. - Common Stock

BioMarin Pharmaceutical

Caris Life Sciences

CRISPR Therapeutics

Exact Sciences Corporation - Common Stock

Exact Sciences

Grifols, S.A. - American Depositary Shares

Grifols

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Krystal Biotech

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Merus

Metsera

Nuvalent

Vaxcyte

PTC Therapeutics

Avidity Biosciences

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Rhythm Pharmaceuticals, Inc. - Common Stock

Comments

Cytokinetics Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO